Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Air Density

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    15 result(s) found for: Air Density. Displaying page 1 of 1.
    EudraCT Number: 2018-002292-18 Sponsor Protocol Number: 7569 Start Date*: 2019-05-24
    Sponsor Name:University Hospital of Montpellier
    Full Title: CT air-trapping characterization for the early identification of Benralizumab responders among eosinophilic asthma patients
    Medical condition: The study population corresponds to severe eosinophilic asthma patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004389-17 Sponsor Protocol Number: TR02-103 Start Date*: 2005-12-28
    Sponsor Name:Transave, Inc
    Full Title: SAFETY AND TOLERABILITY STUDY OF SLIT AMIKACIN 500 MG ONCE DAILY FOR 14 DAYS BY INHALATION IN CYSTIC FIBROSIS STUDY SUBJECTS CHRONICALLY INFECTED WITH PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic Fibrosis with mild to moderate obstructive lung disease and chronic infection with Pseudomonas aeruginosa
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-005289-37 Sponsor Protocol Number: 3_1_6 Start Date*: 2007-05-16
    Sponsor Name:University Witten/Herdecke
    Full Title: Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion
    Medical condition: A model of upper airway obstruction will be used to test the hypothesis that HELIOX 21 when additional oxygen is added (which is a common clinical situation) still can reduce the work of breathing....
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004899-21 Sponsor Protocol Number: TR02-104 Start Date*: 2005-12-22
    Sponsor Name:Transave, Inc.
    Full Title: Safety and tolerability study of SLIT(TM) Amikacin 500 mg once daily for 14 days by inhalation in cystic fibrosis study subjects chronically infected with Pseudomonas aeruginosa.
    Medical condition: Cystic Fibrosis
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004318-82 Sponsor Protocol Number: CTBM100CUS03 Start Date*: 2017-05-15
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    20.0 100000004862 10021860 Infection Pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-006980-22 Sponsor Protocol Number: TR02-105 Start Date*: 2007-06-14
    Sponsor Name:Transave, Inc.
    Full Title: MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011762 Cystic fibrosis LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000300-42 Sponsor Protocol Number: 03AR0298 Start Date*: 2013-01-18
    Sponsor Name:National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
    Full Title: A long-term outcome study with the IL-1 receptor antagonist Anakinra/Kineret® in patients with Neonatal onset multisystem inflammatory disease (Nomid/Cinca syndrome)
    Medical condition: neonatal onset multisystem inflammatory disease (NOMID/CINCA)
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-002677-38 Sponsor Protocol Number: CTX-4430-CF-201 Start Date*: 2016-02-04
    Sponsor Name:Celtaxsys Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks...
    Medical condition: Cystic Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003391-13 Sponsor Protocol Number: D3250C00059 Start Date*: 2019-09-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asth...
    Medical condition: Severe eosinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-008314-40 Sponsor Protocol Number: BAYq3939/12429 Start Date*: 2009-06-22
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared to placebo in subjects with cystic fibrosis
    Medical condition: Cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10011763 Cystic fibrosis lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-000982-30 Sponsor Protocol Number: 4993/15 Start Date*: 2016-08-08
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Personalized pharmacological treatment of chronic obstructive pulmonary disease based on phenotyping: interventional study
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004855 10070975 Chronic obstructive bronchopneumopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000053-21 Sponsor Protocol Number: FLUI-2014-134 Start Date*: 2015-05-05
    Sponsor Name:FLUIDDA nv
    Full Title: Placebo controlled study to assess the effect of Roflumilast in hyperinflated COPD patients in addition to LABA/LAMA therapy using Functional Respiratory Imaging.
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000438-79 Sponsor Protocol Number: CCD-05993AA1-16 Start Date*: 2017-09-11
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: Open label, prospective, exploratory study to investigate the effect of inhaled CHF5993 pMDI on central and peripheral airway dimensions in COPD patients by Functional Respiratory Imaging
    Medical condition: COPD
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000015472 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001743-36 Sponsor Protocol Number: PT003018-00 Start Date*: 2015-12-01
    Sponsor Name:Pearl Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volu...
    Medical condition: Moderate to severe Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000072-42 Sponsor Protocol Number: RG_11-087 Start Date*: 2013-02-06
    Sponsor Name:The University of Birmingham
    Full Title: A randomised phase IIb trial of bevacizumab added to temozolomide ± irinotecan for children with refractory/relapsed neuroblastoma – BEACON-Neuroblastoma Trial
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Ongoing) DK (Ongoing) NL (Ongoing) ES (Ongoing) IT (Ongoing) AT (Completed) DE (Prematurely Ended) BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA